[Guidelines for the management of deep mycosis in neutropenic patients]

Area of Science:

• Medical Mycology
• Hematology
• Infectious Diseases

Background:

• Invasive fungal infections (IFIs) are a significant cause of mortality in immunocompromised patients, particularly those with leukemia or undergoing hematopoietic stem cell transplant (HSCT).
• Systemic candidiasis and invasive pulmonary aspergillosis are major IFIs, with a recent increase in aspergillosis incidence.
• Current Japanese guidelines categorize IFIs into proven, clinically documented, and possible infections, guiding diagnostic and therapeutic approaches.

Purpose of the Study:

• To outline the diagnostic criteria for invasive fungal infections (IFIs) according to Japanese guidelines.
• To describe recommended antifungal prophylaxis and empirical/targeted therapy strategies for IFIs.
• To introduce micafungin (MCFG) as a potential treatment option for both Candida and Aspergillus infections.

Main Methods:

• Review of diagnostic criteria including histological/microbiological evidence, serological/molecular markers (e.g., Aspergillus galactomannan), and radiological findings (e.g., halo sign).
• Analysis of treatment recommendations for different IFI categories and patient risk levels.
• Inclusion of data on antifungal agents like fluconazole (FLCZ), amphotericin B (AMPH), and the newly licensed micafungin (MCFG).

Main Results:

• Japanese guidelines define three diagnostic levels for IFIs: proven, clinically documented, and possible.
• Antifungal prophylaxis is recommended for high-risk patients (e.g., HSCT recipients).
• Empirical therapy (FLCZ or AMPH) for possible IFIs and targeted therapy for proven/clinically documented IFIs are advised, with specific dosing recommendations for candidemia and invasive pulmonary aspergillosis.

Conclusions:

• Micafungin (MCFG) is a newly licensed agent in Japan effective against both Candida and Aspergillus species.
• MCFG shows promise for both empirical and targeted therapy of invasive fungal infections.
• Adherence to diagnostic guidelines and appropriate therapeutic strategies are crucial for managing IFIs in high-risk patient populations.